SEL 24 programme

Drug Profile

SEL 24 programme

Alternative Names: SEL 24; SEL24 program; SEL24-1; SEL24-B489

Latest Information Update: 06 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Selvita
  • Developer Selvita; Theradex
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Preclinical Lymphoma

Most Recent Events

  • 28 Mar 2017 Selvita and Menarini sign licensing agreement for the research, development, manufacturing and commercialisation of SEL24
  • 01 Jan 2017 Phase-I/II clinical trials in Acute myeloid leukaemia in USA (PO) (NCT03008187)
  • 10 Dec 2016 Preclinical trials in Acute myeloid leukaemia in USA (PO) before December 2016 (NCT03008187)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top